Glaspy J - Search Results

1

Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations.

Vansteenkiste J, Poulsen E, Rossi G, Glaspy J. Vansteenkiste J, et al. Among authors: glaspy j. Oncology (Williston Park). 2002 Oct;16(10 Suppl 11):45-55. Oncology (Williston Park). 2002. PMID: 12435173 Clinical Trial.

2

Impact of epoetin alfa in chemotherapy-associated anemia.

Jilani SM, Glaspy JA. Jilani SM, et al. Among authors: glaspy ja. Semin Oncol. 1998 Oct;25(5):571-6. Semin Oncol. 1998. PMID: 9783596 Review.

3

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy.

Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian NS, Armstrong S, O'Byrne J, Rossi G, Colowick AB. Glaspy JA, et al. Br J Cancer. 2002 Jul 29;87(3):268-76. doi: 10.1038/sj.bjc.6600465. Br J Cancer. 2002. PMID: 12177793 Free PMC article. Clinical Trial.

4

The potential for anemia treatment to improve survival in cancer patients.

Glaspy JA. Glaspy JA. Oncology (Williston Park). 2002 Sep;16(9 Suppl 10):35-40. Oncology (Williston Park). 2002. PMID: 12380953 Free article. Review.

5

Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency.

Glaspy JA. Glaspy JA. Oncology (Williston Park). 2002 Sep;16(9 Suppl 10):71-7. Oncology (Williston Park). 2002. PMID: 12380957 Review.

6

Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.

Glaspy JA, Tchekmedyian NS. Glaspy JA, et al. Oncology (Williston Park). 2002 Oct;16(10 Suppl 11):23-9. Oncology (Williston Park). 2002. PMID: 12435170 Clinical Trial.

7

A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.

Glaspy JA, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB. Glaspy JA, et al. Cancer. 2003 Mar 1;97(5):1312-20. doi: 10.1002/cncr.11186. Cancer. 2003. PMID: 12599240 Free article. Clinical Trial.

8

A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer.

Smith RE Jr, Tchekmedyian NS, Chan D, Meza LA, Northfelt DW, Patel R, Austin M, Colowick AB, Rossi G, Glaspy J. Smith RE Jr, et al. Among authors: glaspy j. Br J Cancer. 2003 Jun 16;88(12):1851-8. doi: 10.1038/sj.bjc.6600994. Br J Cancer. 2003. PMID: 12799626 Free PMC article. Clinical Trial.

9

Hematopoietic management in oncology practice. Part 2. Erythropoietic factors.

Glaspy JA. Glaspy JA. Oncology (Williston Park). 2003 Dec;17(12):1724-30; discussion 1731-2, 1735, 1739. Oncology (Williston Park). 2003. PMID: 14723012 Review.

10

Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.

20030125 Study Group Trial; Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G. 20030125 Study Group Trial, et al. Among authors: glaspy j. J Clin Oncol. 2006 May 20;24(15):2290-7. doi: 10.1200/JCO.2005.03.8570. J Clin Oncol. 2006. PMID: 16710026 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

291 results

Search Page

Filters